BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.39
- Market cap
- ₹11.76 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 42.0×Sector 45.9×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Venmax Drugs & Pharmaceuticals Board Meeting Outcome
Venmax Drugs held a board meeting to approve the Directors' Report, AGM date, and appoint/regularize key directors. The meeting outcomes were disclosed under Regulation 30.
Other other announcement announcements
All →Yaan Enterprises Other Announcement
Yaan Enterprises filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoter and promoter group hold 70.65% of the 31,00,000 share capital.
Zen Technologies Other Announcement
Zen Technologies reported no QIP fund utilisation deviation for the quarter ended September 30, 2026. Rs.737.85 Crore of Rs.979.51 Crore raised is utilised per original objects.
Nanta Tech Other Announcement
Nanta Tech confirms no deviation in IPO proceeds utilisation against prospectus objects for the quarter ended 30 September 2026. Auditor certificate attached.
Midwest Other Announcement
Midwest Ltd filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters hold 77.12% of equity; public holds 22.88%.
Rhetan TMT Other Announcement
Rhetan TMT filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31. Promoter and promoter group hold 62.12%, with no transaction or capital event described.
Yajur Fibres Other Announcement
Yajur Fibres Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026. The filing is routine SEBI Reg 31 disclosure with no transaction.